| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.987 | 0.001 | 0.987 | Dopamine transporter inhibitor | 0.742 0.002 DBMET02259 0.962 0.001 DBMET02260 0.655 0.002 DBMET02261 | ||
| 0.953 | 0.002 | 0.953 | 5 Hydroxytryptamine uptake inhibitor | 0.768 0.003 DBMET02259 0.95 0.002 DBMET02260 0.751 0.003 DBMET02261 | ||
| 0.874 | 0.004 | 0.874 | Spasmolytic | 0.636 0.01 DBMET02259 0.759 0.005 DBMET02260 0.469 0.028 DBMET02261 | ||
| 0.844 | 0.002 | 0.851 | Adrenaline uptake inhibitor | 0.614 0.003 DBMET02259 0.851 0.002 DBMET02260 0.614 0.003 DBMET02261 | DBMET02260 | |
| 0.813 | 0.002 | 0.813 | Dopamine uptake inhibitor | 0.382 0.004 DBMET02259 0.696 0.002 DBMET02260 0.254 0.005 DBMET02261 | ||
| 0.763 | 0.003 | 0.763 | Cholinergic antagonist | 0.438 0.006 DBMET02259 0.676 0.003 DBMET02260 0.328 0.012 DBMET02261 | ||
| 0.758 | 0.003 | 0.758 | Acetylcholine antagonist | 0.429 0.006 DBMET02259 0.673 0.003 DBMET02260 0.32 0.012 DBMET02261 | ||
| 0.75 | 0.003 | 0.75 | Acetylcholine M1 receptor antagonist | 0.436 0.005 DBMET02259 0.598 0.003 DBMET02260 0.326 0.01 DBMET02261 | ||
| 0.675 | 0.003 | 0.675 | Acetylcholine muscarinic antagonist | 0.379 0.005 DBMET02259 0.544 0.004 DBMET02260 0.261 0.013 DBMET02261 | ||
| 0.665 | 0.005 | 0.665 | HERG channel blocker | 0.276 0.056 DBMET02259 0.656 0.005 DBMET02260 0.251 0.066 DBMET02261 | ||
| 0.639 | 0.005 | 0.639 | Potassium channel (Voltage-sensitive) blocker | 0.242 0.071 DBMET02259 0.636 0.005 DBMET02260 0.225 0.08 DBMET02261 | ||
| 0.606 | 0.016 | 0.7 | Toll-Like receptor 7 agonist | 0.7 0.009 DBMET02260 | DBMET02260 | |
| 0.59 | 0.003 | 0.59 | 5 Hydroxytryptamine uptake stimulant | 0.529 0.004 DBMET02259 0.568 0.003 DBMET02260 0.506 0.004 DBMET02261 | ||
| 0.599 | 0.017 | 0.692 | Toll-Like receptor agonist | 0.692 0.009 DBMET02260 | DBMET02260 | |
| 0.568 | 0.003 | 0.568 | Acetylcholine M2 receptor antagonist | 0.235 0.005 DBMET02259 0.403 0.004 DBMET02260 0.136 0.013 DBMET02261 | ||
| 0.558 | 0.003 | 0.558 | Dopamine D4 agonist | 0.109 0.013 DBMET02259 0.437 0.004 DBMET02260 | ||
| 0.557 | 0.008 | 0.557 | Psychostimulant | 0.473 0.013 DBMET02259 0.478 0.013 DBMET02260 0.392 0.024 DBMET02261 | ||
| 0.553 | 0.004 | 0.553 | Antihistaminic | 0.107 0.05 DBMET02259 0.255 0.014 DBMET02260 | ||
| 0.532 | 0.004 | 0.532 | Histamine antagonist | 0.092 0.053 DBMET02259 0.244 0.014 DBMET02260 | ||
| 0.535 | 0.009 | 0.542 | Potassium channel blocker | 0.542 0.008 DBMET02260 | DBMET02260 | |
| 0.471 | 0.003 | 0.471 | Acetylcholine M4 receptor antagonist | 0.151 0.01 DBMET02259 0.322 0.004 DBMET02260 0.11 0.022 DBMET02261 | ||
| 0.482 | 0.036 | 0.491 | Histamine release inhibitor | 0.462 0.044 DBMET02259 0.491 0.032 DBMET02260 0.472 0.04 DBMET02261 | DBMET02260 | |
| 0.455 | 0.009 | 0.455 | 5 Hydroxytryptamine antagonist | 0.119 0.065 DBMET02259 0.323 0.016 DBMET02260 | ||
| 0.466 | 0.045 | 0.466 | Antiobesity | 0.396 0.067 DBMET02260 | ||
| 0.405 | 0.004 | 0.405 | Histamine H1 receptor antagonist | 0.117 0.033 DBMET02259 0.163 0.021 DBMET02260 | ||
| 0.386 | 0.003 | 0.386 | Acetylcholine M3 receptor antagonist | 0.174 0.009 DBMET02259 0.313 0.004 DBMET02260 0.102 0.018 DBMET02261 | ||
| 0.376 | 0.008 | 0.376 | Anesthetic local | 0.322 0.011 DBMET02259 0.271 0.016 DBMET02260 0.238 0.022 DBMET02261 | ||
| 0.351 | 0.006 | 0.351 | Alpha 2b adrenoreceptor antagonist | 0.196 0.024 DBMET02259 0.215 0.021 DBMET02260 0.11 0.066 DBMET02261 | ||
| 0.319 | 0.003 | 0.319 | Sphingomyelinase inhibitor | 0.206 0.009 DBMET02259 0.212 0.008 DBMET02260 0.123 0.039 DBMET02261 | ||
| 0.392 | 0.088 | 0.625 | Analgesic | 0.489 0.053 DBMET02259 0.556 0.035 DBMET02260 0.625 0.023 DBMET02261 | DBMET02261 | |
| 0.297 | 0.007 | 0.297 | Acetylcholine nicotinic antagonist | 0.156 0.019 DBMET02259 0.234 0.01 DBMET02260 0.129 0.027 DBMET02261 | ||
| 0.289 | 0.005 | 0.289 | Dopamine agonist | 0.096 0.029 DBMET02259 0.19 0.011 DBMET02260 | ||
| 0.286 | 0.004 | 0.286 | Acetylcholine M5 receptor antagonist | 0.127 0.011 DBMET02259 0.183 0.005 DBMET02260 0.07 0.031 DBMET02261 | ||
| 0.341 | 0.059 | 0.371 | 5 Hydroxytryptamine release stimulant | 0.36 0.054 DBMET02259 0.351 0.056 DBMET02260 0.371 0.052 DBMET02261 | DBMET02261 | |
| 0.311 | 0.038 | 0.316 | Anticonvulsant | 0.316 0.036 DBMET02260 | DBMET02260 | |
| 0.278 | 0.008 | 0.278 | Alpha 2c adrenoreceptor antagonist | 0.159 0.029 DBMET02259 0.167 0.026 DBMET02260 0.088 0.077 DBMET02261 | ||
| 0.273 | 0.011 | 0.273 | Bronchodilator | 0.165 0.027 DBMET02259 0.243 0.013 DBMET02260 0.13 0.039 DBMET02261 | ||
| 0.28 | 0.022 | 0.295 | Cholinergic | 0.295 0.019 DBMET02260 0.115 0.114 DBMET02261 | DBMET02260 | |
| 0.289 | 0.037 | 0.289 | 5 Hydroxytryptamine 1E antagonist | 0.279 0.045 DBMET02259 0.179 0.155 DBMET02260 | ||
| 0.253 | 0.004 | 0.253 | 5 Hydroxytryptamine 3 antagonist | 0.054 0.043 DBMET02259 0.149 0.009 DBMET02260 | ||
| 0.284 | 0.037 | 0.284 | Anesthetic general | 0.28 0.038 DBMET02259 0.136 0.13 DBMET02260 | ||
| 0.249 | 0.009 | 0.249 | Dopamine D4 antagonist | 0.092 0.029 DBMET02260 | ||
| 0.294 | 0.059 | 0.294 | Cardiotonic | |||
| 0.248 | 0.019 | 0.248 | 5 Hydroxytryptamine 2B antagonist | 0.124 0.057 DBMET02259 0.11 0.072 DBMET02260 | ||
| 0.231 | 0.005 | 0.231 | Acetylcholine muscarinic agonist | 0.077 0.023 DBMET02259 0.153 0.01 DBMET02260 | ||
| 0.234 | 0.008 | 0.234 | Dopamine D3 antagonist | 0.067 0.039 DBMET02259 0.105 0.023 DBMET02260 | ||
| 0.245 | 0.026 | 0.245 | Antipruritic | 0.164 0.079 DBMET02259 0.243 0.027 DBMET02260 0.162 0.081 DBMET02261 | ||
| 0.22 | 0.011 | 0.22 | Acetylcholine agonist | 0.099 0.047 DBMET02259 0.187 0.016 DBMET02260 0.079 0.066 DBMET02261 | ||
| 0.213 | 0.004 | 0.213 | Acetylcholine M1 receptor agonist | 0.07 0.019 DBMET02259 0.135 0.009 DBMET02260 | ||
| 0.23 | 0.027 | 0.364 | Alpha-N-acetylglucosaminidase inhibitor | 0.268 0.02 DBMET02259 0.316 0.015 DBMET02260 0.364 0.011 DBMET02261 | DBMET02261 | |
| 0.211 | 0.018 | 0.211 | Dopamine antagonist | 0.064 0.059 DBMET02259 0.083 0.046 DBMET02260 | ||
| 0.252 | 0.066 | 0.302 | Tyrosine 3 hydroxylase inhibitor | 0.293 0.036 DBMET02259 0.26 0.059 DBMET02260 0.302 0.032 DBMET02261 | DBMET02261 | |
| 0.284 | 0.105 | 0.284 | Vasodilator, peripheral | 0.253 0.125 DBMET02259 0.266 0.116 DBMET02260 0.238 0.137 DBMET02261 | ||
| 0.19 | 0.015 | 0.19 | Alpha 2a adrenoreceptor antagonist | 0.1 0.036 DBMET02259 0.11 0.032 DBMET02260 | ||
| 0.183 | 0.012 | 0.183 | Opioid kappa receptor antagonist | 0.134 0.019 DBMET02259 0.077 0.063 DBMET02260 | ||
| 0.175 | 0.007 | 0.175 | Acetylcholine release stimulant | 0.126 0.039 DBMET02259 0.11 0.065 DBMET02260 | ||
| 0.187 | 0.019 | 0.187 | 5 Hydroxytryptamine 3A agonist | 0.182 0.021 DBMET02259 0.137 0.043 DBMET02260 0.132 0.046 DBMET02261 | ||
| 0.196 | 0.031 | 0.196 | 5 Hydroxytryptamine 2 antagonist | 0.095 0.076 DBMET02259 0.107 0.067 DBMET02260 | ||
| 0.184 | 0.02 | 0.184 | Alpha 2 adrenoreceptor antagonist | 0.105 0.044 DBMET02259 0.113 0.04 DBMET02260 | ||
| 0.17 | 0.01 | 0.196 | Acetylcholine M3 receptor agonist | 0.196 0.005 DBMET02260 0.118 0.035 DBMET02261 | DBMET02260 | |
| 0.271 | 0.111 | 0.314 | Cholesterol antagonist | 0.314 0.083 DBMET02259 0.261 0.117 DBMET02260 0.305 0.088 DBMET02261 | DBMET02259 | |
| 0.163 | 0.004 | 0.163 | Acetylcholine M5 receptor agonist | 0.092 0.025 DBMET02259 0.107 0.016 DBMET02260 | ||
| 0.224 | 0.066 | 0.245 | MAP kinase kinase 3 inhibitor | 0.208 0.1 DBMET02259 0.245 0.036 DBMET02260 0.228 0.059 DBMET02261 | DBMET02260 | |
| 0.166 | 0.008 | 0.193 | Glutamate (mGluR7) agonist | 0.105 0.051 DBMET02259 0.193 0.005 DBMET02260 0.121 0.029 DBMET02261 | DBMET02260 | |
| 0.161 | 0.006 | 0.161 | Nicotinic alpha4beta2 receptor antagonist | 0.137 0.011 DBMET02259 0.156 0.007 DBMET02260 0.133 0.012 DBMET02261 | ||
| 0.21 | 0.058 | 0.21 | P-glycoprotein inhibitor | 0.175 0.084 DBMET02260 | ||
| 0.155 | 0.005 | 0.155 | 5 Hydroxytryptamine 3A antagonist | 0.061 0.054 DBMET02259 0.121 0.009 DBMET02260 | ||
| 0.162 | 0.013 | 0.162 | Dopamine D1 antagonist | 0.146 0.015 DBMET02259 0.062 0.048 DBMET02260 0.057 0.054 DBMET02261 | ||
| 0.165 | 0.018 | 0.177 | Ca2+-transporting ATPase inhibitor | 0.177 0.008 DBMET02259 0.157 0.029 DBMET02260 0.169 0.014 DBMET02261 | DBMET02259 | |
| 0.164 | 0.02 | 0.164 | Dopamine D2 antagonist | 0.063 0.047 DBMET02260 | ||
| 0.162 | 0.024 | 0.162 | 5 Hydroxytryptamine 2C antagonist | 0.072 0.071 DBMET02259 | ||
| 0.143 | 0.013 | 0.143 | Neuronal nicotinic receptor antagonist | 0.095 0.026 DBMET02259 0.119 0.018 DBMET02260 0.08 0.036 DBMET02261 | ||
| 0.243 | 0.114 | 0.243 | Nootropic | |||
| 0.131 | 0.004 | 0.138 | Nicotinic alpha3beta2 receptor antagonist | 0.11 0.006 DBMET02259 0.138 0.004 DBMET02260 0.117 0.005 DBMET02261 | DBMET02260 | |
| 0.128 | 0.008 | 0.128 | Nicotinic receptor alpha7 subunit antagonist | 0.06 0.029 DBMET02259 0.107 0.011 DBMET02260 0.052 0.039 DBMET02261 | ||
| 0.143 | 0.03 | 0.143 | 5 Hydroxytryptamine 2A antagonist | 0.101 0.046 DBMET02260 | ||
| 0.127 | 0.018 | 0.127 | Histamine H2 receptor antagonist | 0.076 0.073 DBMET02259 0.098 0.037 DBMET02260 | ||
| 0.136 | 0.028 | 0.158 | Prolactin inhibitor | 0.158 0.019 DBMET02259 0.112 0.045 DBMET02260 0.131 0.031 DBMET02261 | DBMET02259 | |
| 0.118 | 0.01 | 0.12 | 5 Hydroxytryptamine 6 antagonist | 0.056 0.04 DBMET02259 0.12 0.01 DBMET02260 0.058 0.039 DBMET02261 | DBMET02260 | |
| 0.238 | 0.133 | 0.306 | Interleukin 2 agonist | 0.295 0.077 DBMET02259 0.25 0.118 DBMET02260 0.306 0.069 DBMET02261 | DBMET02261 | |
| 0.17 | 0.065 | 0.202 | Arachidonic acid antagonist | 0.194 0.039 DBMET02259 0.18 0.053 DBMET02260 0.202 0.031 DBMET02261 | DBMET02261 | |
| 0.111 | 0.006 | 0.288 | Nicotinic receptor alpha4 subunit antagonist | 0.087 0.011 DBMET02259 0.288 0.003 DBMET02260 0.224 0.003 DBMET02261 | DBMET02260 | |
| 0.299 | 0.195 | 0.381 | Caspase 9 stimulant | 0.381 0.123 DBMET02259 0.257 0.244 DBMET02260 0.334 0.159 DBMET02261 | DBMET02259 | |
| 0.171 | 0.067 | 0.204 | Thrombolytic | 0.148 0.083 DBMET02259 0.204 0.05 DBMET02260 0.179 0.063 DBMET02261 | DBMET02260 | |
| 0.13 | 0.032 | 0.13 | Opioid antagonist | 0.116 0.038 DBMET02259 | ||
| 0.174 | 0.077 | 0.174 | Lipocortins synthesis antagonist | 0.152 0.102 DBMET02260 | ||
| 0.097 | 0.005 | 0.097 | 5 Hydroxytryptamine 3B antagonist | 0.034 0.028 DBMET02260 | ||
| 0.248 | 0.156 | 0.277 | GABA C receptor rho-3 antagonist | 0.277 0.132 DBMET02259 0.239 0.164 DBMET02260 0.267 0.14 DBMET02261 | DBMET02259 | |
| 0.204 | 0.116 | 0.287 | DNA synthesis inhibitor | 0.244 0.071 DBMET02259 0.235 0.078 DBMET02260 0.287 0.048 DBMET02261 | DBMET02261 | |
| 0.098 | 0.01 | 0.098 | 5-Alpha-reductase inhibitor | 0.07 0.014 DBMET02259 0.063 0.015 DBMET02260 0.044 0.021 DBMET02261 | ||
| 0.108 | 0.022 | 0.108 | Leukotriene synthesis inhibitor | 0.065 0.049 DBMET02259 0.101 0.025 DBMET02260 | ||
| 0.104 | 0.019 | 0.111 | Glycine receptor agonist | 0.111 0.015 DBMET02259 0.087 0.031 DBMET02260 0.093 0.026 DBMET02261 | DBMET02259 | |
| 0.188 | 0.103 | 0.221 | Cyclic AMP phosphodiesterase inhibitor | 0.172 0.12 DBMET02259 0.221 0.08 DBMET02260 0.199 0.094 DBMET02261 | DBMET02260 | |
| 0.1 | 0.016 | 0.1 | Sigma receptor antagonist | 0.065 0.025 DBMET02259 0.055 0.031 DBMET02260 | ||
| 0.09 | 0.011 | 0.09 | Nicotinic receptor alpha3 subunit antagonist | 0.063 0.018 DBMET02259 0.072 0.015 DBMET02260 0.051 0.024 DBMET02261 | ||
| 0.078 | 0.006 | 0.084 | Acetylcholine M4 receptor agonist | 0.084 0.005 DBMET02260 | DBMET02260 | |
| 0.083 | 0.012 | 0.083 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.078 | 0.008 | 0.189 | Nicotinic receptor beta4 subunit antagonist | 0.072 0.009 DBMET02259 0.189 0.003 DBMET02260 0.175 0.003 DBMET02261 | DBMET02260 | |
| 0.102 | 0.036 | 0.102 | Acetylcholine nicotinic agonist | 0.079 0.059 DBMET02259 0.096 0.04 DBMET02260 0.074 0.065 DBMET02261 | ||
| 0.112 | 0.048 | 0.139 | Creatine kinase inhibitor | 0.139 0.029 DBMET02259 0.103 0.056 DBMET02260 0.129 0.035 DBMET02261 | DBMET02259 | |
| 0.097 | 0.033 | 0.097 | Opioid mu receptor antagonist | 0.092 0.035 DBMET02259 | ||
| 0.08 | 0.016 | 0.08 | Histamine H3 receptor antagonist | 0.053 0.025 DBMET02260 | ||
| 0.078 | 0.015 | 0.078 | Histamine agonist | 0.074 0.017 DBMET02260 | ||
| 0.125 | 0.062 | 0.125 | DNA repair enzyme inhibitor | 0.114 0.085 DBMET02260 | ||
| 0.085 | 0.024 | 0.085 | 5 Hydroxytryptamine 3 agonist | 0.082 0.025 DBMET02259 | ||
| 0.105 | 0.044 | 0.105 | Antineoplastic alkaloid | 0.104 0.045 DBMET02259 | ||
| 0.125 | 0.068 | 0.173 | Nav1.3 sodium channel blocker | 0.147 0.05 DBMET02259 0.148 0.049 DBMET02260 0.173 0.035 DBMET02261 | DBMET02261 | |
| 0.187 | 0.133 | 0.262 | Interleukin agonist | 0.235 0.09 DBMET02259 0.217 0.105 DBMET02260 0.262 0.07 DBMET02261 | DBMET02261 | |
| 0.228 | 0.174 | 0.309 | Calcium channel activator | 0.212 0.196 DBMET02259 0.309 0.083 DBMET02260 0.295 0.097 DBMET02261 | DBMET02260 | |
| 0.08 | 0.028 | 0.081 | Glutamate (mGluR7) antagonist | 0.081 0.026 DBMET02259 | DBMET02259 | |
| 0.113 | 0.062 | 0.113 | Mucolytic | 0.109 0.066 DBMET02259 0.099 0.079 DBMET02260 0.096 0.084 DBMET02261 | ||
| 0.068 | 0.018 | 0.075 | Alpha-mannosidase inhibitor | 0.075 0.013 DBMET02259 0.061 0.025 DBMET02260 0.068 0.019 DBMET02261 | DBMET02259 | |
| 0.076 | 0.026 | 0.076 | Androgen agonist | 0.061 0.04 DBMET02259 0.072 0.029 DBMET02260 0.058 0.044 DBMET02261 | ||
| 0.064 | 0.016 | 0.064 | Histamine H4 receptor antagonist | |||
| 0.129 | 0.082 | 0.179 | Nav1.6 sodium channel blocker | 0.173 0.033 DBMET02259 0.136 0.072 DBMET02260 0.179 0.029 DBMET02261 | DBMET02261 | |
| 0.051 | 0.005 | 0.056 | Nicotinic alpha3beta4 receptor agonist | 0.038 0.012 DBMET02259 0.056 0.004 DBMET02260 0.041 0.009 DBMET02261 | DBMET02260 | |
| 0.094 | 0.051 | 0.096 | Histamine N-methyltransferase inhibitor | 0.089 0.057 DBMET02259 0.096 0.049 DBMET02260 0.091 0.055 DBMET02261 | DBMET02260 | |
| 0.281 | 0.239 | 0.349 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.349 0.152 DBMET02260 0.297 0.217 DBMET02261 | DBMET02260 | |
| 0.162 | 0.121 | 0.162 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | |||
| 0.064 | 0.025 | 0.064 | Acetylcholine M2 receptor agonist | 0.054 0.036 DBMET02260 | ||
| 0.057 | 0.019 | 0.057 | Glutamate (mGluR5) agonist | 0.042 0.039 DBMET02260 | ||
| 0.088 | 0.051 | 0.091 | mTOR complex 2 inhibitor | 0.091 0.045 DBMET02259 0.081 0.067 DBMET02260 0.084 0.06 DBMET02261 | DBMET02259 | |
| 0.057 | 0.021 | 0.057 | Dopamine D5 antagonist | 0.05 0.025 DBMET02259 | ||
| 0.049 | 0.013 | 0.05 | Glutamate (mGluR3) antagonist | 0.033 0.031 DBMET02259 0.05 0.013 DBMET02260 0.034 0.029 DBMET02261 | DBMET02260 | |
| 0.057 | 0.024 | 0.057 | HCV NS3/NS4A protease inhibitor | 0.056 0.024 DBMET02260 | ||
| 0.101 | 0.068 | 0.101 | Expectorant | 0.097 0.072 DBMET02259 | ||
| 0.068 | 0.036 | 0.068 | Alpha 1d adrenoreceptor antagonist | |||
| 0.081 | 0.049 | 0.088 | Na+ K+ transporting ATPase inhibitor | 0.086 0.045 DBMET02259 0.084 0.047 DBMET02260 0.088 0.043 DBMET02261 | DBMET02261 | |
| 0.089 | 0.057 | 0.089 | Bromodomain-containing protein 2 inhibitor | |||
| 0.123 | 0.091 | 0.123 | Lipid peroxidase inhibitor | 0.118 0.096 DBMET02259 | ||
| 0.099 | 0.067 | 0.276 | Nav1.1 sodium channel blocker | 0.276 0.01 DBMET02259 0.242 0.013 DBMET02261 | DBMET02259 | |
| 0.063 | 0.032 | 0.063 | Ca(v)3.2 blocker | 0.063 0.032 DBMET02259 | ||
| 0.053 | 0.022 | 0.06 | Mannosidase inhibitor | 0.06 0.017 DBMET02259 0.049 0.027 DBMET02260 0.056 0.02 DBMET02261 | DBMET02259 | |
| 0.063 | 0.033 | 0.063 | Nicotinic neuronal receptor agonist | 0.061 0.035 DBMET02260 | ||
| 0.096 | 0.068 | 0.103 | Anabolic | 0.099 0.064 DBMET02259 0.101 0.062 DBMET02260 0.103 0.058 DBMET02261 | DBMET02261 | |
| 0.161 | 0.133 | 0.161 | Antiamyloidogenic | |||
| 0.055 | 0.026 | 0.055 | Glutamate (mGluR group I) agonist | |||
| 0.059 | 0.032 | 0.059 | Nicotinic alpha7 receptor agonist | 0.05 0.043 DBMET02260 | ||
| 0.045 | 0.018 | 0.045 | Farnesoid X receptor agonist | 0.037 0.028 DBMET02260 | ||
| 0.142 | 0.116 | 0.179 | ATPase inhibitor | 0.179 0.058 DBMET02259 0.139 0.122 DBMET02261 | DBMET02259 | |
| 0.088 | 0.063 | 0.146 | Triose-phosphate isomerase inhibitor | 0.116 0.034 DBMET02259 0.108 0.041 DBMET02260 0.146 0.021 DBMET02261 | DBMET02261 | |
| 0.088 | 0.065 | 0.088 | Alpha adrenoreceptor antagonist | |||
| 0.168 | 0.144 | 0.186 | 5 Hydroxytryptamine 3E antagonist | 0.186 0.089 DBMET02260 0.168 0.141 DBMET02261 | DBMET02260 | |
| 0.105 | 0.082 | 0.105 | Alkylator | 0.096 0.093 DBMET02259 | ||
| 0.069 | 0.047 | 0.069 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.03 | 0.009 | 0.03 | 5-Alpha-reductase 2 inhibitor | 0.025 0.01 DBMET02259 0.02 0.013 DBMET02260 0.018 0.015 DBMET02261 | ||
| 0.198 | 0.18 | 0.206 | Antithrombotic | 0.206 0.17 DBMET02260 | DBMET02260 | |
| 0.033 | 0.015 | 0.033 | Sigma 2 receptor antagonist | |||
| 0.038 | 0.02 | 0.038 | Ceramide glucosyltransferase inhibitor | 0.036 0.024 DBMET02259 | ||
| 0.198 | 0.184 | 0.217 | Vasodilator, coronary | 0.217 0.166 DBMET02259 0.209 0.174 DBMET02261 | DBMET02259 | |
| 0.068 | 0.055 | 0.068 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.03 | 0.017 | 0.036 | Nicotinic alpha4beta2 receptor agonist | 0.026 0.023 DBMET02259 0.036 0.011 DBMET02260 0.032 0.015 DBMET02261 | DBMET02260 | |
| 0.068 | 0.055 | 0.068 | Alpha 1b adrenoreceptor antagonist | |||
| 0.08 | 0.067 | 0.089 | Estrogen-related receptor beta agonist | 0.089 0.043 DBMET02259 0.082 0.062 DBMET02261 | DBMET02259 | |
| 0.114 | 0.102 | 0.132 | Vanilloid 1 agonist | 0.132 0.062 DBMET02260 0.127 0.072 DBMET02261 | DBMET02260 | |
| 0.029 | 0.018 | 0.031 | 1,3-Beta-glucan synthase inhibitor | 0.031 0.012 DBMET02260 | DBMET02260 | |
| 0.028 | 0.018 | 0.028 | Sigma 1 receptor antagonist | |||
| 0.032 | 0.022 | 0.041 | Glutamate (mGluR3) agonist | 0.041 0.009 DBMET02260 0.036 0.015 DBMET02261 | DBMET02260 | |
| 0.023 | 0.013 | 0.023 | Geranylgeranyltransferase I inhibitor | 0.019 0.018 DBMET02259 | ||
| 0.041 | 0.031 | 0.045 | Guanylate cyclase inhibitor | 0.045 0.026 DBMET02259 0.038 0.037 DBMET02260 0.042 0.031 DBMET02261 | DBMET02259 | |
| 0.087 | 0.078 | 0.165 | UDP-glucose 4-epimerase inhibitor | 0.117 0.045 DBMET02259 0.122 0.042 DBMET02260 0.165 0.024 DBMET02261 | DBMET02261 | |
| 0.06 | 0.051 | 0.062 | Prolactin release inhibitor | 0.062 0.046 DBMET02259 | DBMET02259 | |
| 0.203 | 0.194 | 0.243 | Immunosuppressant | 0.243 0.154 DBMET02259 0.232 0.164 DBMET02261 | DBMET02259 | |
| 0.024 | 0.017 | 0.024 | 5 Hydroxytryptamine 4 agonist | 0.024 0.017 DBMET02260 | ||
| 0.089 | 0.082 | 0.097 | Mediator release inhibitor | 0.097 0.073 DBMET02260 | DBMET02260 | |
| 0.021 | 0.014 | 0.021 | Nociceptin (N/OFQ) receptor agonist | 0.021 0.014 DBMET02259 | ||
| 0.059 | 0.053 | 0.059 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.188 | 0.182 | 0.201 | Transcription factor NF kappa B inhibitor | 0.201 0.168 DBMET02259 | DBMET02259 | |
| 0.069 | 0.063 | 0.069 | Analgesic, opioid | |||
| 0.054 | 0.051 | 0.068 | Opioid delta receptor antagonist | 0.068 0.041 DBMET02259 | DBMET02259 | |
| 0.073 | 0.07 | 0.091 | Glycine receptor antagonist | 0.078 0.06 DBMET02259 0.085 0.049 DBMET02260 0.091 0.042 DBMET02261 | DBMET02261 | |
| 0.146 | 0.143 | 0.22 | Aldehyde oxidase inhibitor | 0.218 0.096 DBMET02259 0.147 0.142 DBMET02260 0.22 0.095 DBMET02261 | DBMET02261 | |
| 0.06 | 0.058 | 0.06 | Alpha 1a adrenoreceptor antagonist | |||
| 0.164 | 0.164 | 0.272 | Superoxide dismutase inhibitor | 0.226 0.092 DBMET02259 0.199 0.118 DBMET02260 0.272 0.062 DBMET02261 | DBMET02261 | |
| 0.028 | 0.028 | 0.028 | Potassium channel (Inward rectifier) 1 blocker | 0.028 0.027 DBMET02260 | DBMET02260 | |
| 0.123 | 0.126 | 0.143 | Interferon gamma antagonist | 0.129 0.113 DBMET02259 0.138 0.096 DBMET02260 0.143 0.087 DBMET02261 | DBMET02261 | |
| 0.088 | 0.091 | 0.09 | mTOR complex 1 inhibitor | 0.09 0.085 DBMET02259 | DBMET02259 | |
| 0.163 | 0.168 | 0.212 | RNA-directed DNA polymerase inhibitor | 0.202 0.096 DBMET02259 0.173 0.146 DBMET02260 0.212 0.083 DBMET02261 | DBMET02261 | |
| 0.033 | 0.04 | 0.087 | Dopamine D5 agonist | 0.048 0.019 DBMET02259 0.06 0.012 DBMET02260 0.087 0.005 DBMET02261 | DBMET02261 | |
| 0.086 | 0.095 | 0.121 | Cystathionine beta-synthase inhibitor | 0.121 0.057 DBMET02259 | DBMET02259 | |
| 0.075 | 0.085 | 0.08 | CC chemokine 5 receptor agonist | 0.08 0.066 DBMET02259 0.08 0.066 DBMET02261 | DBMET02261 | |
| 0.01 | 0.023 | 0.023 | NMDA receptor phencyclidine site antagonist | 0.022 0.006 DBMET02259 0.023 0.006 DBMET02261 | DBMET02261 | |
| 0.024 | 0.037 | 0.029 | Estrogen-related receptor gamma antagonist | 0.029 0.017 DBMET02259 | DBMET02259 | |
| 0.039 | 0.054 | 0.055 | Glucose-6-phosphate isomerase inhibitor | 0.049 0.031 DBMET02259 0.044 0.042 DBMET02260 0.055 0.024 DBMET02261 | DBMET02261 | |
| 0.119 | 0.134 | 0.134 | Pregnane X receptor agonist | 0.134 0.088 DBMET02259 | DBMET02259 | |
| 0.092 | 0.107 | 0.099 | Microtubule formation inhibitor | 0.098 0.095 DBMET02259 0.099 0.093 DBMET02261 | DBMET02261 | |
| 0.099 | 0.114 | 0.163 | Nav1.2 sodium channel blocker | 0.125 0.078 DBMET02259 0.127 0.075 DBMET02260 0.163 0.05 DBMET02261 | DBMET02261 | |
| 0.045 | 0.061 | 0.106 | Glucosylceramidase inhibitor | 0.106 0.007 DBMET02260 0.086 0.013 DBMET02261 | DBMET02260 | |
| 0.022 | 0.04 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.015 DBMET02260 | DBMET02260 | |
| 0.044 | 0.062 | 0.055 | Sphingosine kinase 2 inhibitor | 0.055 0.038 DBMET02260 | DBMET02260 | |
| 0.055 | 0.074 | 0.068 | Beta 3 adrenoreceptor antagonist | 0.068 0.038 DBMET02260 0.063 0.048 DBMET02261 | DBMET02260 | |
| 0.037 | 0.056 | 0.053 | Opioid agonist | 0.051 0.039 DBMET02260 0.053 0.036 DBMET02261 | DBMET02261 | |
| 0.035 | 0.055 | 0.046 | Farnesyltransferase inhibitor | 0.046 0.032 DBMET02259 | DBMET02259 | |
| 0.045 | 0.065 | 0.067 | Carbamoyl phosphate synthetase inhibitor | 0.058 0.045 DBMET02260 0.067 0.037 DBMET02261 | DBMET02261 | |
| 0.011 | 0.031 | 0.017 | Nicotinic alpha4 receptor agonist | 0.017 0.01 DBMET02260 | DBMET02260 | |
| 0.073 | 0.093 | 0.097 | NADH dehydrogenase inhibitor | 0.079 0.078 DBMET02259 0.09 0.057 DBMET02260 0.097 0.047 DBMET02261 | DBMET02261 | |
| 0.078 | 0.101 | 0.098 | Ferrochelatase inhibitor | 0.09 0.083 DBMET02259 0.098 0.073 DBMET02261 | DBMET02261 | |
| 0.036 | 0.064 | 0.048 | Potassium channel (Inward rectifier) blocker | 0.048 0.037 DBMET02260 | DBMET02260 | |
| 0.03 | 0.063 | 0.04 | Thymidine kinase inhibitor | 0.04 0.029 DBMET02260 | DBMET02260 | |
| 0.037 | 0.071 | 0.046 | Topoisomerase II beta inhibitor | 0.046 0.039 DBMET02261 | DBMET02261 | |
| 0.044 | 0.08 | 0.09 | Phosphofructokinase-1 inhibitor | 0.07 0.048 DBMET02259 0.09 0.036 DBMET02261 | DBMET02261 | |
| 0.066 | 0.103 | 0.082 | MAP kinase kinase 7 inhibitor | 0.079 0.05 DBMET02260 0.082 0.041 DBMET02261 | DBMET02261 | |
| 0.072 | 0.11 | 0.204 | GABA C receptor agonist | 0.104 0.062 DBMET02259 0.139 0.039 DBMET02260 0.204 0.02 DBMET02261 | DBMET02261 | |
| 0.053 | 0.091 | 0.06 | Beta 2 adrenoreceptor agonist | 0.06 0.051 DBMET02260 | DBMET02260 | |
| 0.017 | 0.057 | 0.033 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.033 0.026 DBMET02259 | DBMET02259 | |
| 0.053 | 0.094 | 0.071 | Glutamate dehydrogenase inhibitor | 0.071 0.055 DBMET02261 | DBMET02261 | |
| 0.109 | 0.153 | 0.147 | Adenylate cyclase stimulant | 0.14 0.081 DBMET02260 0.147 0.068 DBMET02261 | DBMET02261 | |
| 0.078 | 0.122 | 0.098 | Adenylate kinase inhibitor | 0.091 0.085 DBMET02260 0.098 0.071 DBMET02261 | DBMET02261 | |
| 0.021 | 0.066 | 0.04 | Opioid delta receptor agonist | 0.035 0.024 DBMET02260 0.04 0.02 DBMET02261 | DBMET02261 | |
| 0.037 | 0.084 | 0.063 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.05 0.048 DBMET02259 0.063 0.031 DBMET02261 | DBMET02261 | |
| 0.072 | 0.12 | 0.108 | GABA C receptor rho-1 antagonist | 0.095 0.069 DBMET02260 0.108 0.053 DBMET02261 | DBMET02261 | |
| 0.035 | 0.083 | 0.048 | Aconitate hydratase inhibitor | 0.048 0.042 DBMET02261 | DBMET02261 | |
| 0.044 | 0.093 | 0.095 | Antineoplastic antibiotic | 0.073 0.062 DBMET02259 0.095 0.049 DBMET02261 | DBMET02261 | |
| 0.066 | 0.115 | 0.102 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.096 0.058 DBMET02260 0.102 0.052 DBMET02261 | DBMET02261 | |
| 0.014 | 0.064 | 0.16 | Dipeptidyl peptidase I inhibitor | 0.16 0.003 DBMET02260 0.145 0.003 DBMET02261 | DBMET02260 | |
| 0.083 | 0.135 | 0.107 | Cyclooxygenase 3 inhibitor | 0.107 0.093 DBMET02260 | DBMET02260 | |
| 0.032 | 0.087 | 0.059 | Argininosuccinate synthase inhibitor | 0.052 0.045 DBMET02260 0.059 0.038 DBMET02261 | DBMET02261 | |
| 0.046 | 0.104 | 0.065 | Aminopeptidase I inhibitor | 0.065 0.061 DBMET02261 | DBMET02261 | |
| 0.051 | 0.111 | 0.067 | Glutamate (mGluR6) antagonist | 0.063 0.057 DBMET02260 0.067 0.046 DBMET02261 | DBMET02261 | |
| 0.028 | 0.096 | 0.041 | Kainate receptor agonist | 0.041 0.03 DBMET02261 | DBMET02261 | |
| 0.032 | 0.1 | 0.047 | Potassium channel (ATP-sensitive) activator | 0.047 0.035 DBMET02260 | DBMET02260 | |
| 0.033 | 0.102 | 0.05 | Potassium channel (Inward rectifier) activator | 0.05 0.036 DBMET02260 | DBMET02260 | |
| 0.032 | 0.101 | 0.054 | Biliverdin reductase inhibitor | 0.054 0.047 DBMET02261 | DBMET02261 | |
| 0.082 | 0.152 | 0.109 | Cathepsin H inhibitor | 0.109 0.092 DBMET02260 | DBMET02260 | |
| 0.048 | 0.12 | 0.09 | Ornithine decarboxylase inhibitor | 0.09 0.056 DBMET02261 | DBMET02261 | |
| 0.041 | 0.115 | 0.053 | Pregnane X receptor antagonist | 0.053 0.05 DBMET02261 | DBMET02261 | |
| 0.038 | 0.118 | 0.06 | Beta adrenoreceptor antagonist | 0.06 0.056 DBMET02260 | DBMET02260 | |
| 0.146 | 0.226 | 0.2 | Nitric-oxide synthase stimulant | 0.199 0.09 DBMET02260 0.2 0.088 DBMET02261 | DBMET02261 | |
| 0.04 | 0.121 | 0.066 | Glutamate decarboxylase inhibitor | 0.066 0.06 DBMET02261 | DBMET02261 | |
| 0.027 | 0.11 | 0.054 | Alcohol oxidase inhibitor | 0.054 0.041 DBMET02261 | DBMET02261 | |
| 0.059 | 0.142 | 0.096 | ATPase (Vacuolar H+) inhibitor | 0.096 0.046 DBMET02259 | DBMET02259 | |
| 0.176 | 0.26 | 0.314 | Antibacterial | 0.278 0.152 DBMET02260 0.314 0.125 DBMET02261 | DBMET02261 | |
| 0.043 | 0.127 | 0.08 | Phospholipase D inhibitor | 0.07 0.054 DBMET02260 0.08 0.035 DBMET02261 | DBMET02261 | |
| 0.066 | 0.155 | 0.123 | GABA C receptor antagonist | 0.098 0.081 DBMET02260 0.123 0.049 DBMET02261 | DBMET02261 | |
| 0.008 | 0.098 | 0.045 | Squalene synthetase inhibitor | 0.045 0.016 DBMET02259 0.033 0.021 DBMET02261 | DBMET02259 | |
| 0.11 | 0.209 | 0.16 | Succinate dehydrogenase inhibitor | 0.16 0.095 DBMET02261 | DBMET02261 | |
| 0.033 | 0.135 | 0.066 | Histidine decarboxylase inhibitor | 0.066 0.055 DBMET02261 | DBMET02261 | |
| 0.059 | 0.167 | 0.084 | Granulocyte macrophage colony stimulating factor agonist | 0.084 0.064 DBMET02261 | DBMET02261 | |
| 0.015 | 0.136 | 0.312 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.312 0.004 DBMET02259 0.274 0.004 DBMET02261 | DBMET02259 | |
| 0.028 | 0.156 | 0.067 | Phenylalanine 4-hydroxylase inhibitor | 0.067 0.049 DBMET02261 | DBMET02261 | |
| 0.062 | 0.193 | 0.082 | T cell inhibitor | 0.082 0.059 DBMET02259 0.078 0.076 DBMET02261 | DBMET02259 | |
| 0.104 | 0.241 | 0.137 | Phospholipase C inhibitor | 0.137 0.135 DBMET02261 | DBMET02261 | |
| 0.105 | 0.255 | 0.154 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.154 0.127 DBMET02260 | DBMET02260 | |
| 0.095 | 0.255 | 0.156 | Neurotrophic factor enhancer | 0.156 0.13 DBMET02261 | DBMET02261 | |
| 0.18 | 0.345 | 0.296 | 5 Hydroxytryptamine release inhibitor | 0.276 0.194 DBMET02260 0.296 0.17 DBMET02261 | DBMET02261 | |
| 0.054 | 0.22 | 0.279 | Nav1.4 sodium channel blocker | 0.275 0.005 DBMET02259 0.279 0.004 DBMET02261 | DBMET02261 | |
| 0.058 | 0.228 | 0.097 | DOPA decarboxylase inhibitor | 0.097 0.082 DBMET02261 | DBMET02261 | |
| 0.006 | 0.189 | 0.02 | Somatostatin 3 antagonist | 0.02 0.014 DBMET02260 | DBMET02260 | |
| 0.061 | 0.245 | 0.16 | Peroxidase inhibitor | 0.16 0.073 DBMET02261 | DBMET02261 | |
| 0.02 | 0.272 | 0.114 | NMDA receptor antagonist | 0.114 0.039 DBMET02261 | DBMET02261 | |
| 0.087 | 0.359 | 0.184 | Hypoxia-inducible factor 1 alpha inhibitor | 0.184 0.173 DBMET02259 | DBMET02259 | |
| 0.027 | 0.308 | 0.305 | Glutamate receptor antagonist | 0.252 0.015 DBMET02259 0.305 0.01 DBMET02261 | DBMET02261 | |
| 0.06 | 0.367 | 0.166 | Vasodilator | 0.166 0.136 DBMET02261 | DBMET02261 | |
| 0.094 | 0.652 | 0.313 | Calcium channel L-type activator | 0.313 0.146 DBMET02261 | DBMET02261 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |